Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036192 · ClinicalTrials.gov registry record · Phase 2
Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00036192 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 200 participants.
The verdict
NCT00036192, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and efficacy of FK614 in type 2 diabetic subjects receiving sulfonylurea (SU) monotherapy.
Interventions
- DRUG FK614
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036192
The ClinicalTrials.gov registry entry for NCT00036192 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FK614 is the first listed.
NCT00036192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036192 about?
NCT00036192 is a clinical study titled "Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea". The purpose of the study is to assess the safety and efficacy of FK614 in type 2 diabetic subjects receiving sulfonylurea (SU) monotherapy.
What is the current status of trial NCT00036192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2002-02. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00036192?
The interventions under investigation include: FK614 (DRUG).
Who is sponsoring clinical trial NCT00036192?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.